HER2+ BC: Residual Disease After Neoadjuvant Therapy

Video

HER2+ BC: Residual Disease After Neoadjuvant Therapy

Case: A 49-Year-Old Woman With HER2+ Breast Cancer

H & P

  • A 49-year-old woman was referred by gynecology for a mass in her right breast
  • No children, menopause at age 45
  • No history of cardiovascular disease, otherwise good health
  • PE: revealed a woman of normal weight (BMI = 21 kg/m2), with a palpable mass in her right breast

Imaging

  • Mammogram revealed 3.5-cm tumor in right breast
  • CT: confirmed a tumor in right breast with no lymph node involvement

Biopsy and labs:

  • Histology: ductal, grade 2
  • ER(-), PR (-)
  • HER2IHC: 3+
  • BRCA1/2: negative

Treatment

  • Diagnosed with ER/PR negativeHER2+ breast cancer; she received neoadjuvant TCH-P (docetaxel + carboplatin + trastuzumab + pertuzumab and achieved a partial response
    • Residual disease of 1.5 cm after neoadjuvant therapy
  • Underwent mastectomy
  • After discussing with her the options for adjuvant therapy, benefits and risks of each, and her goals, she was started on ado-trastuzumab emtansine (T-DM1)
  • At present, she has completed 3 cycles of T-DM1
    • Reports numbness in her fingers, “like wearing gloves” that sometimes interferes with small tasks like buttoning a shirt

Recent Videos
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
1 KOL is featured in this series.
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Related Content